Amalgamated Bank Chemo Centryx, Inc. Transaction History

Amalgamated Bank

$12.1 Billion
Q3 2024

Shares

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 09, 2022	BUY	$22.17 - $51.8 $4,478 - $10,463	202 Added 2.13%	9,672 $500,000
Q2 2022 Aug 15, 2022	BUY	$15.36 - $27.51 $43,023 - $77,055	2,801 Added 42.0%	9,470 $235,000
Q1 2022 Jun 30, 2022	SELL	$22.22 - $39.12 $11,754 - $20,694	-529 Reduced 7.35%	6,669 $167,000
Q4 2021 Feb 15, 2022	BUY	$18.38 - $40.5 $132,299 - $291,519	7,198 New	7,198 $262,000
Q2 2021 Aug 16, 2021	SELL	$9.59 - $50.88 $67,705 - $359,212	-7,060 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$49.53 - $68.4 $34,175 - $47,196	-690 Reduced 8.9%	7,060 $362,000
Q4 2020 Feb 12, 2021	BUY	$47.25 - $65.16 $1,937 - $2,671	41 Added 0.53%	7,750 $479,000
Q3 2020 Oct 30, 2020	BUY	$46.35 - $61.69 $27,578 - $36,705	595 Added 8.36%	7,709 $422,000
Q2 2020 Aug 10, 2020	SELL	$38.58 - $65.07 $3,009 - $5,075	-78 Reduced 1.08%	7,114 $409,000
Q1 2020 May 13, 2020	SELL	$32.73 - $50.78 $4,811 - $7,464	-147 Reduced 2.0%	7,192 $289,000
Q4 2019 Feb 13, 2020	BUY	$6.81 - $39.55 $49,978 - $290,257	7,339 New	7,339 $290,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.